Easter 2017 Enrolment Closure Dates

To ensure the safe and complete enrolment of patients into our Warfarin Care program, enrolments will be closed between the following dates:

Community patients: Closing 5pm Thursday 30 March 2017 and re-opening 9am Tuesday 18 April 2017.

Hospital patients: Closing 5pm Monday 3 April 2017 and re-opening 9am Tuesday 18 April 2017.

 

Warfarin Care Enrolment and Procedure

Sullivan Nicolaides Pathology's Warfarin Care program is a service provided to patients of Sullivan Nicolaides Pathology's regular referring doctors.

IMPORTANT NOTICE

For patient safety reasons, we will not accept patients into our Warfarin Care program where we do not have regular communications with the patient's general practitioner.

This precludes patients of general practitioners who do not usually refer to Sullivan Nicolaides Pathology and patients directly from public hospitals. Sullivan Nicolaides Pathology reserves the right to refuse enrolment of any patient for patient safety reasons.

Before enrolment, please assess your patient's eligilibility for our Warfarin Care program according to our Enrolment & Eligibility criteria below. 

 

PLEASE FAX THE COMPLETED FORM TO (07) 3377 8461

Warfarin Care Enrolment Form - Interactive PDF document

Warfarin Care Patient Guide - PDF document

Warfarin Care Program Billing Information - PDF document

Warfarin Care Discharge Summary - PDF document

Warfarin Care SMS Patient Registration Brochure - PDF document

Warfarin Care Investigative Protocols

Links of Interest

 

Please read the below carefully before enrolling your patient in the Warfarin Care program.

For more information, please contact Warfarin Care on Ph (07) 3377 8578 or Fax (07) 3377 8461.

 

ENROLMENT STEPS

 

Step 1 - Before enrolment, please:

  • assess your patient's eligibility for our Warfarin Care program according to our Eligibility criteria.
  • provide your patient with adequate dosing instructions until Warfarin Care Support have notified you and your patient that the enrolment process is complete. Allow at least 3 working days.

 

Step 2 - Doctor, nurse, or practice manager must fax the completed enrolment application to Warfarin Care Support to enrol your patient. Please retain this original enrolment application for future reference. 

Your patient's eligibility will be assessed and we will notify you if our program is not suitable for your patient.

The referring doctor must manage the patient's heparin therapy, including low molecular weight heparin such as Clexane. Heparin therapy (UF or LMWH) should continue until INR is in the therapeutic range for at least 48 hours.

We cannot commence enrolments on Fridays, weekends, or public holidays.  Enrolment days will be limited prior to Easter, Christmas and New Year to allow the safe transfer of your patient onto our program. 

Enrolment in our Warfarin Care program is contingent upon all parties - doctor, patient, and laboratory - understanding and accepting their roles and responsibilities as outlined in the Sullivan Nicolaides Pathology Handbook for Doctors.

 

ELIGIBILITY CRITERIA 

 

To be eligible for enrolment on our program, your patient must:

  • be taking Warfarin (not Dindevan medication)
  • have a minimum enrolment period of one month
  • have a General Practitioner who refers their patients to Sullivan Nicolaides Pathology 
  • have a valid contact phone number and mailing address
  • be able to comprehend and record verbal dose instructions
  • be able to comply with dose instructions (or has a carer who can comply)
  • be able to attend for testing on scheduled dates, subject to exceptional circumstances
  • not have been discharged from a Warfarin Care program due to non-compliance
  • not require a narrow target range (less than one unit)
  • not require daily INR levels
  • not require acute care

 

 

ONGOING PATIENT ELIGIBILITY FOR WARFARIN CARE

 

Patients who were eligible on enrolment will become ineligible for our Warfarin Care program if they:

  • require a narrow target range
  • require daily INR levels
  • are non-compliant
  • become unable to follow verbal or written dose instructions
  • are abusive to Sullivan Nicolaides Pathology staff
  • develop complex clinical conditions or become unstable where one-on-one management by their own referring doctor is necessary
  • experience ongoing difficulties attending on scheduled test dates - for example, patients who reside in remote areas or whose employment requires frequent travel

 

You will be advised of our concerns regarding your patient's suitability for our program. If these concerns are not resolved, then we will return the responsibility for managing your patient's Warfarin therapy to you.

 

WARFARIN INVESTIGATIVE PROTOCOLS

Therapeutic INR Ranges Range of International Normalised Ratio (INR) recommended for specific applications of warfarin therapy
Elevated INR Management Guidelines for the management of an elevated INR, with or without bleeding
Warfarin Bleeding Risks

Risk factors for bleeding complications of Warfarin therapy

 


LINKS OF INTEREST

ASTH Website - The Australasian Society of Thrombosis and Haemostasis